These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20233345)

  • 21. Leukocyte-poor blood components: issues and indications.
    Lichtiger B; Leparc GF
    Crit Rev Clin Lab Sci; 1991; 28(5-6):387-403. PubMed ID: 1772586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacterial contamination of platelet concentrates: where are we today?
    Goldman M
    Vox Sang; 2004 Jul; 87 Suppl 2():90-2. PubMed ID: 15209888
    [No Abstract]   [Full Text] [Related]  

  • 23. [Reducing the infectious risk of labile blood products].
    Noël L
    Presse Med; 1997 Apr; 26(14):685-90. PubMed ID: 9180891
    [No Abstract]   [Full Text] [Related]  

  • 24. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
    Klein HG; Glynn SA; Ness PM; Blajchman MA;
    Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood product-associated bacterial sepsis.
    Goldman M; Blajchman MA
    Transfus Med Rev; 1991 Jan; 5(1):73-83. PubMed ID: 1802278
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of blood culture contamination rate by an educational intervention.
    Eskira S; Gilad J; Schlaeffer P; Hyam E; Peled N; Karakis I; Riesenberg K; Schlaeffer F; Borer A
    Clin Microbiol Infect; 2006 Aug; 12(8):818-21. PubMed ID: 16842584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current trends in blood component therapy: the evolution of a safer, more effective product.
    Baranowski L
    J Intraven Nurs; 1992; 15(3):136-51. PubMed ID: 1608013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands.
    de Korte D; Curvers J; de Kort WL; Hoekstra T; van der Poel CL; Beckers EA; Marcelis JH
    Transfusion; 2006 Mar; 46(3):476-85. PubMed ID: 16533293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and significance of the bacterial contamination of blood components.
    Blajchman MA
    Dev Biol (Basel); 2002; 108():59-67. PubMed ID: 12220143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivation of microbial contaminants of blood components.
    AuBuchon JP; Dodd RY
    Clin Lab Med; 1992 Dec; 12(4):787-803. PubMed ID: 1286565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. International forum on 'Perioperative blood salvage': a Spanish contribution.
    Muñoz M; Gómez-Luque A; Ramírez G;
    Vox Sang; 2007 Jan; 92(1):90. PubMed ID: 17181596
    [No Abstract]   [Full Text] [Related]  

  • 32. Concepts for bacterial safety of blood components in Germany.
    Montag T
    Transfus Apher Sci; 2001 Jun; 24(3):251-2. PubMed ID: 11791698
    [No Abstract]   [Full Text] [Related]  

  • 33. [Bacterial contamination of platelet concentrates].
    Araújo F; Alves V; Oliveira G; Fonseca C; Araújo AR
    Sangre (Barc); 1996 Dec; 41(6):483-4. PubMed ID: 9148429
    [No Abstract]   [Full Text] [Related]  

  • 34. Bacterial contamination in blood components and preventative strategies: an overview.
    Vasconcelos E; Seghatchian J
    Transfus Apher Sci; 2004 Oct; 31(2):155-63. PubMed ID: 15501419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of 2% chlorhexidine tincture compared with 10% aqueous povidone-iodine for venipuncture site disinfection: Effects on blood culture contamination rates.
    Suwanpimolkul G; Pongkumpai M; Suankratay C
    J Infect; 2008 May; 56(5):354-9. PubMed ID: 18407355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2008 Congress of the ESFH in Düsseldorf, Germany.
    Moog R
    Transfus Apher Sci; 2009 Aug; 41(1):23-6. PubMed ID: 19556166
    [No Abstract]   [Full Text] [Related]  

  • 37. Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening.
    McDonald CP
    Transfus Med; 2006 Dec; 16(6):381-96. PubMed ID: 17163869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood component therapy.
    Fasano R; Luban NL
    Pediatr Clin North Am; 2008 Apr; 55(2):421-45, ix. PubMed ID: 18381094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yersinia enterocolitica contamination of blood products. Connecticut State Medical Society Committee on Organ and Tissue Transfers.
    Badon SJ; Cable RG
    Conn Med; 1992 Jun; 56(6):287-9. PubMed ID: 1638859
    [No Abstract]   [Full Text] [Related]  

  • 40. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
    Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
    Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.